Subject mortality

Ministry of Health, Mortality and Morbidity during the London Fog of December 1952, Rep. of Public Health and Related Subject No, 95. H.M. Stationery Office, London, 1954. 

Before 1980, the mortality rate among younger addicts was up to 20 times higher than that among control subjects it was 2—3 times higher for older ad-... 

ECASS-II was designed to test a lower dose of rt-PA (0.9 mg/kg) during the same 0-6-hours time period after stroke onset, using similar inclusion criteria as in ECASS-I. ° The primary endpoint was the proportion with a favorable outcome on the mRS scale (defined as a score of 0 or 1). There was no difference in this outcome between rt-PA-treated and placebo controls (40% vs. 37%, p = 0.28). A separate analysis of the 158 subjects enrolled within 3 hours of stroke onset also showed no difference in the proportion with a favorable outcome (42% vs. 38%, p = 0.63) this result, however, must be treated with caution because in ECASS-II there was a substantially lower number of patients treated within 3 hours of stroke onset, compared to the 1995 NINDS rt-PA study. Parenchymal hematoma on post-treatment CT was seen in 12% of rt-PA-treated and 3% of placebo patients (p < 0.001). The 90-day mortality rate was 11 % for the rt-PA group and 11 % for the placebo group (p = 0.54). Protocol violations were much less frequent in ECASS-II compared to ECASS-I (9% vs. 18%), probably because of standardized training in CT interpretation at the study sites. 

Lisboa et al. analyzed the safety and efficacy of lAT on the basis of current published data. They found a total of 27 studies (10 patients minimum) with a total of 852 patients who received lAT and 100 control subjects. There were more favorable outcomes in the lAT than in the control group (41.5% vs. 23%), with a lower mortality rate for lAT (27.2% vs. 40%). The lAT group had an OR of 2.4 for favorable outcomes, despite a higher frequency of symptomatic ICH (9.5% vs. 3%). In addition, they found a trend toward better outcomes with combined IV rt-PA and lAT than with lAT alone. They also remarked that lAT-treated supratentorial strokes are more likely to have favorable outcomes than infratentorial ones (42.2% vs. 25.6%). 

The Interventional Management of Stroke (IMS I) Study was a multicenter, open-labeled, single-arm pilot study in which 80 patients (median NIHSS 18) were enrolled to receive IV rt-PA (0.6 mg/kg, 60 mg maximum, 15% of the dose as a bolus with the remainder administered over 30 minutes) within 3 hours of stroke onset (median time to initiation 140 minutes). " Additional rt-PA was subsequently administered via a microcatheter at the site of the thrombus in 62 of the 80 patients, up to a total dose of 22 mg over 2 hours of infusion or until complete recanalization. Primary comparisons were with similar subsets of the placebo and rt-PA-treated subjects from the NINDS rt-PA Stroke Trial. The 3-month mortality in IMS I subjects (16%) was numerically lower but not statistically different than the mortality of the placebo (24%) or rt-PA-treated subjects (21%) in the NINDS rt-PA Stroke Trial. The rate of symptomatic ICH (6.3%) in IMS I subjects was similar to that of the rt-PA-treated subjects (6.6%) but higher than the rate in the... 

Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) have been shown to improve vascular outcomes due to their cholesterol-lowering effects as well as multiple pleiotropic effects. In high-risk populations, statin therapy is known to reduce the risk of vascular events such as myocardial infarction and stroke. A meta-analysis of 10 trials involving 79,494 subjects showed that statin therapy reduced the incidence of stroke by 18%, major coronary events by 27%, and all-cause mortality by 15%. The SPARCL trial recently showed that high-dose HMG-CoA reductase inhibitors prevent recurrent stroke and transient ischemic attacks. ... 

The reasons for the observed differences in mortality between aspirin-treated patients in 1ST and CAST are unclear. The findings may relate to baseline differences between the treated groups. CAST had a younger age profile (72% under 70 compared to 38% in 1ST), excluded some patients with severe stroke, and likely included more subjects with lacunar stroke, an etiology associated with lower mortality and less disability. 

You see that all 80 patients have their mortality status reported and that just by scanning the frequency tabulation you can tell that more subjects receiving treatment a have died. You also see from the chi-square p- value of 0.0333 that treatment a has significantly more deaths at an alpha level of. 05. 

Chromium has proved effective in counteracting the deleterious effects of cadmium in rats and of vanadium in chickens. High mortality rates and testicular atrophy occurred in rats subjected to an intraperitoneal injection of cadmium salts however, pretreatment with chromium ameliorated these effects (Stacey et al. 1983). The Cr-Cd relationship is not simple. In some cases, cadmium is known to suppress adverse effects induced in Chinese hamster (Cricetus spp.) ovary cells by Cr (Shimada et al. 1998). In southwestern Sweden, there was an 80% decline in chromium burdens in liver of the moose (Alces alces) between 1982 and 1992 from 0.21 to 0.07 mg Cr/kg FW (Frank et al. 1994). During this same period in this locale, moose experienced an unknown disease caused by a secondary copper deficiency due to elevated molybdenum levels as well as chromium deficiency and trace element imbalance (Frank et al. 1994). In chickens (Gallus sp.), 10 mg/kg of dietary chromium counteracted adverse effects on albumin metabolism and egg shell quality induced by 10 mg/kg of vanadium salts (Jensen and Maurice 1980). Additional research on the beneficial aspects of chromium in living resources appears warranted, especially where the organism is subjected to complex mixtures containing chromium and other potentially toxic heavy metals. 

Mink 1.0 mg/kg diet daily for 4 months then every other day for 4 months alternating with control diet High mortality after 4 months when subjected to cold stress significant placental transfer to the fetus 9... 

Diazinon adversely affects survival of developing mallard embryos when the eggshell surface is subjected for 30 seconds to concentrations 25 to 34 times higher than recommended field application rates. Mortality patterns were similar for solutions applied in water or in oil (Table 16.3). 

A wealth of epidemiological, clinical, and experimental studies link estrogens with cardiovascular disease (CVD). This evidence has promoted CVD as a key area within the extragenital effects of estrogens. The question is of interest because it directly affects the wide clinical use of estrogens as contraceptive agents or as principal constituents of hormonal therapy (HT) formulations in postmenopausal women. The significance of the subject is further reinforced by the relevance of CVD as a cause of mortality and morbidity in both women and men. 

---